During the recent session, AbCellera Biologics Inc (NASDAQ:ABCL)’s traded shares were 1.08 million, with the beta value of the company hitting 0.46. At the last check today, the stock’s price was $3.45, reflecting an intraday loss of -2.13% or -$0.08. The 52-week high for the ABCL share is $5.62, that puts it down -62.9 from that peak though still a striking 32.17% gain since the share price plummeted to a 52-week low of $2.34. The company’s market capitalization is $1.02B, and the average intraday trading volume over the past 10 days was 4.46 million shares, and the average trade volume was 2.91 million shares over the past three months.
AbCellera Biologics Inc (ABCL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.22. ABCL has a Sell rating from 0 analyst(s) out of 9 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
AbCellera Biologics Inc (ABCL) registered a -2.13% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -2.13% in intraday trading to $3.45, hitting a weekly high. The stock’s 5-day price performance is 16.71%, and it has moved by 27.48% in 30 days. Based on these gigs, the overall price performance for the year is -37.30%. The short interest in AbCellera Biologics Inc (NASDAQ:ABCL) is 16.57 million shares and it means that shorts have 6.36 day(s) to cover.
The consensus price target of analysts on Wall Street is $5, which implies an increase of 31.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $5 respectively. As a result, ABCL is trading at a discount of -44.93% off the target high and -44.93% off the low.
AbCellera Biologics Inc (ABCL) estimates and forecasts
Statistics show that AbCellera Biologics Inc has underperformed its competitors in share price, compared to the industry in which it operates. AbCellera Biologics Inc (ABCL) shares have gone up 11.44% during the last six months, with a year-to-date growth rate less than the industry average at -15.69% against 16.50.
While earnings are projected to return -15.13% in 2025.
ABCL Dividends
AbCellera Biologics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders
AbCellera Biologics Inc insiders own 27.93% of total outstanding shares while institutional holders control 39.58%, with the float percentage being 54.91%. BAKER BROS. ADVISORS LP is the largest shareholder of the company, while 201.0 institutions own stock in it. As of 2024-06-30, the company held over 27.53 million shares (or 9.4033% of all shares), a total value of $81.48 million in shares.
The next largest institutional holding, with 21.91 million shares, is of BAILLIE GIFFORD & CO’s that is approximately 7.4852% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $64.86 million.
Also, the Mutual Funds coming in first place with the largest holdings of AbCellera Biologics Inc (ABCL) shares are iShares Biotechnology ETF and Vanguard Valley Forge Fds-Baillie Gifford Global Pos Impact Stock Fd. Data provided on Oct 31, 2024 indicates that iShares Biotechnology ETF owns about 1.46 shares. This amounts to just over 0.49 percent of the company’s overall shares, with a $5.06 million market value. The same data shows that the other fund manager holds slightly less at 454.44, or about 0.15% of the stock, which is worth about $1.58 million.
